project id: TCGA-KIRP; case submitter id: TCGA-J7-A8I2; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.89; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.71; rna integrity number: 7.9; age at index: 75; days to birth: -27431; ethnicity: not hispanic or latino; gender: male; race: asian; vital status: Alive; year of birth: 1938; age at diagnosis: 27431; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage I; ajcc clinical t: T1; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage I; ajcc pathologic t: T1b; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 307.0; icd 10 code: C64.1; last known disease status: not reported; morphology: 8260/3; primary diagnosis: Papillary adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Kidney, NOS; synchronous malignancy: No; tissue or organ of origin: Kidney, NOS; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 167; days to sample procurement: 0; initial weight: 240.0; portion submitter id: TCGA-J7-A8I2-01A-12; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 18.0; percent tumor cells: 80.0; percent tumor nuclei: 95.0;